Please assess the completion status of the following clinical trial:

Trial Title: Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men 18 years or older with a histologic diagnosis of clinically localized prostate cancer prior to radical prostatectomy as defined by:~   * Clinical stage T1-T2b~  * Prostate specific Antigen (PSA) less than 20~  * Gleason score 7-10~2. Patient's tumor must be considered surgically resectable .~3. Eastern Cooperative Group (ECOG) performance status of 0-1.~4. Life expectancy greater than 2 years.~5. Able to understand and give informed consent.~6. Laboratory values must be within specified limits.~Exclusion Criteria:~1. Patients with locally advanced or high risk disease not meeting the criteria defined above.~2. Patients who have a total testosterone less than 280 ng/dL.~3. Patients who are receiving any other investigational therapy.~4. Patients with an active serious infection or other serious underlying medical condition.~5. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.~6. Histologic evidence of small cell carcinoma of the prostate.~7. Patients who are currently receiving active therapy for other neoplastic disorders.~8. Patients who are receiving any androgens, estrogens or progestational agents.~9. Patients who are taking drugs or herbal supplements which affect androgen metabolism (e.g., spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, St. John's wort).~10. Patients who have chronic active hepatitis.~11. Patients taking any of the following medications who cannot discontinue these medications for three months during administration of ketoconazole; statin cholesterol medications, cyclosporine, isoniazid, rifampin, terfenadine, triazolam or astemizole.~12. Patients who have history of cerebrovascular accident, deep venous thrombosis, pulmonary emboli, unstable angina or clinical congestive heart failure.~13. Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained.~14. Patients unwilling to use contraceptives while on study.~15. Patients with a risk of nodal involvement of greater than 10% should have received a bone scan and CT of the pelvis prior to screening for the study as part of standard of care.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Goserelin + dutasteride
- Group 2 (Type: ACTIVE_COMPARATOR): Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
- Group 3 (Type: ACTIVE_COMPARATOR): Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).